SCHEMBL3403523

SCHEMBL3403523

CCOC(=O)c1sc(Cl)nc1C(=O)NNC=O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.45
CYP1A2 P05177 1/20 0.45
SMN1; SMN2 Q16637 5/20 0.41
GAA P10253 3/20 0.41
HPGD P15428 6/20 0.39
NPC1 O15118 3/20 0.39
MAPT P10636 3/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
KDM4E B2RXH2 5/20 0.38
RAB9A P51151 4/20 0.38
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
TP53 P04637 2/20 0.38
HSD17B10 Q99714 1/20 0.38
HSP90AA1 P07900 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
DHODH Q02127 1/20 0.37
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3399751 0.84 GAA (0.48) ALDH1A1CYP1A2SMN1; SMN2GAAHPGD
SCHEMBL1554058 0.81 ALDH1A1 (0.49) ALDH1A1CYP1A2SMN1; SMN2GAAHPGD
SCHEMBL1505552 0.80 ALDH1A1 (0.66) ALDH1A1CYP1A2GAAHPGDNPC1
SCHEMBL1553145 0.80 SMN1; SMN2 (0.48) ALDH1A1CYP1A2SMN1; SMN2GAAHPGD
SCHEMBL1553485 0.79 ALDH1A1 (0.47) ALDH1A1CYP1A2SMN1; SMN2GAAHPGD
SCHEMBL1553279 0.79 ALDH1A1 (0.47) ALDH1A1CYP1A2SMN1; SMN2GAAHPGD
SCHEMBL1553046 0.78 ALDH1A1 (0.54) ALDH1A1CYP1A2GAAHPGDNPC1
SCHEMBL1553063 0.78 ALDH1A1 (0.54) ALDH1A1CYP1A2SMN1; SMN2GAAHPGD
SCHEMBL1552481 0.77 ALDH1A1 (0.53) ALDH1A1CYP1A2GAAHPGDNPC1
SCHEMBL1553587 0.77 ALDH1A1 (0.45) ALDH1A1CYP1A2SMN1; SMN2GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
EP-2158199-A1 PIPERIDINE COMPOUNDS AND USES THEREOF AstraZeneca AB (SE) 2010-03-03 EP disclosed
WO-2008152418-A1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2008-12-18 WO disclosed
WO-2008152418-A1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2008-12-18 WO disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 NISCH, PIR, QDPR ALDH1A1 243/4885CYP1A2 156/4885SMN1; SMN2 2282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.